KEAP1 and lung carcinoma: As the top one ERs ranked by their associated interactions in lung adenocarcinoma (LUAD), KEAP1 mutation could affect treatment outcomes of ICB through modulating immune infiltration and immune‐related pathways in lung cancer.31